每经AI快讯，周二，ImmunityBio(IBRX.US)盘前续涨超13%，今年以来已暴涨178%，现报6.31美元。 （文章来源：每日经济新闻） ...

Core Viewpoint - ImmunityBio's stock has surged over 178% this year, with a pre-market increase of over 13% on Tuesday, currently trading at $6.31 per share [1] Group 1: Company Developments - ImmunityBio announced that the FDA is seeking additional information related to its supplemental biologics license application for Anktiva in combination with BCG for treating non-muscle invasive bladder cancer in patients with papillary tumors [1] - The FDA has requested certain additional information to support a potential resubmission of the application initially submitted last year for the papillary indication [1] - The company plans to submit the required information to the FDA within the next 30 days, and the additional information does not involve initiating or designing new clinical trials [1]

Core Viewpoint - ImmunityBio's stock has surged over 13% in pre-market trading and has increased by 178% year-to-date, currently priced at $6.31 [1] Group 1: FDA Interaction - The U.S. Food and Drug Administration (FDA) is seeking additional information related to ImmunityBio's supplemental biologics license application concerning Anktiva combined with Bacillus Calmette-Guérin (BCG) for treating non-muscle invasive bladder cancer in patients with papillary tumors [1] - The FDA has suggested that the company provide certain additional information to support a potential resubmission of the application initially submitted last year for the papillary indication [1] - ImmunityBio plans to submit the required information to the FDA within the next 30 days, and the additional information does not involve initiating or designing new clinical trials [1]

As of Jan. 20, 2026, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength on days when prices go down. When compared to a stock’s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the RSI is above 70, according to ...

Core Insights - Three stocks in the health care sector are signaling potential warnings for momentum-focused investors as of January 20, 2026 [1] Group 1: Overbought Stocks - Venus Concept Inc (NASDAQ:VERO) has an RSI value of 95.9, with shares gaining 451.8% to close at $7.89 on Friday, and a 52-week high of $14.50 [2][5] - ImmunityBio Inc (NASDAQ:IBRX) has an RSI value of 95.4, with shares rising 39.8% to close at $5.52 on Friday, and a year-to-date increase of over 100% [2][5]

Core Viewpoint - ImmunityBio, Inc. has engaged in a Type B End-of-Phase meeting with the U.S. FDA regarding its supplemental Biologics License Application for ANKTIVA® in treating BCG-unresponsive non-muscle invasive bladder cancer [1] Group 1 - The meeting focused on the clinical status of ANKTIVA® (nogapendekin alfa inbakicept) combined with Bacillus Calmette-Guérin (BCG) [1]

Several biotech and healthcare stocks posted notable gains in after-hours trading on Friday, driven by regulatory developments, financing updates, and investor sentiment.Atossa Therapeutics, Inc. (ATOS) rose 12.98% to $0.69, up $0.080 after announcing that the U.S. Food and Drug Administration's Office of Orphan Products Development granted Orphan Drug Designation to (Z)-endoxifen for the treatment of Duchenne muscular dystrophy. The designation marks a significant milestone for the company's pipeline.Immu ...

Artificial intelligence is the greatest investment opportunity of our lifetime. The time to invest in groundbreaking AI is now, and this stock is a steal! AI is eating the world—and the machines behind it are ravenous. Each ChatGPT query, each model update, each robotic breakthrough consumes massive amounts of energy. In fact, AI is already pushing global power grids to the brink. Wall Street is pouring hundreds of billions into artificial intelligence—training smarter chatbots, automating industries, and b ...

Core Insights - ImmunityBio's shares increased by 39.8% on Friday and an additional 9.4% in after-hours trading following the release of updated efficacy and safety data from the QUILT-106 clinical study [2][8] - The QUILT-106 study is assessing an allogeneic CD19 CAR-NK therapy in combination with Roche's Rituxan for patients with Waldenström non-Hodgkin's lymphoma, showing promising results [3][4] Study Results - Updated data from the QUILT-106 study indicate durable complete responses and sustained disease control in patients with Waldenström NHL, with 100% disease control observed to date and responses extending up to 15 months [4][8] - The treatment regimen involves off-the-shelf CD19 CAR-NK cells combined with Rituxan, administered in an outpatient setting without the need for chemotherapy-based lymphodepletion [5][9] - Four patients have been enrolled in the study, all of whom remain in clinical disease control, with two patients demonstrating durable complete remission at seven and 15 months, respectively [6][10] Market Performance - Over the past six months, ImmunityBio's shares have surged by 106%, significantly outperforming the industry average growth of 22.1% [7] Future Developments - Enrollment and follow-up in the QUILT-106 study are ongoing, with further clinical updates expected as more patients become evaluable [10] - A follow-up study is planned to evaluate the combination of NK-CAR with ImmunityBio's IL-15 superagonist, Anktiva, and Roche's Rituxan to enhance current results in indolent lymphoma [10] Additional Programs - ImmunityBio is making progress in its first-line BCG-naïve NMIBC program, with enrollment in the QUILT-2.005 study exceeding expectations, targeting full enrollment by Q2 2026 [12] - The QUILT-2.005 study is evaluating Anktiva in combination with BCG, showing statistically significant improvements in complete response duration compared to BCG alone [14]

Core Insights - Artificial intelligence (AI) is identified as the greatest investment opportunity of the current era, with a strong emphasis on the urgency to invest now [1][13] - The energy demands of AI technologies are significant, with data centers consuming as much energy as small cities, leading to concerns about power grid capacity and rising electricity prices [2][3] Investment Opportunity - A specific company is highlighted as a critical player in the AI energy sector, owning essential energy infrastructure assets that are poised to benefit from the increasing energy demands of AI [3][7] - This company is not a chipmaker or cloud platform but is positioned as a "toll booth" operator in the AI energy boom, collecting fees from energy exports and benefiting from the onshoring trend driven by tariffs [5][6] Financial Position - The company is noted for being debt-free and holding a significant cash reserve, amounting to nearly one-third of its market capitalization, which positions it favorably compared to other energy firms burdened by debt [8][10] - It also has a substantial equity stake in another AI-related company, providing investors with indirect exposure to multiple growth opportunities without the associated premium costs [9] Market Trends - The article discusses the broader trends of AI, energy, tariffs, and onshoring, indicating that this company is strategically aligned with these developments [6][14] - The influx of talent into the AI sector is expected to drive continuous innovation and advancements, reinforcing the potential for growth in AI investments [12] Future Outlook - The company is positioned at the heart of America's next-generation power strategy, particularly in nuclear energy, which is seen as a clean and reliable power source for the future [7][14] - The potential for significant returns is emphasized, with projections suggesting a possible 100% return within 12 to 24 months for investors who act now [15][19]